Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gut
Autors principals: Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2017
Matèries:
Hepatology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595101/
https://ncbi.nlm.nih.gov/pubmed/27418632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-311609
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars